Real-world therapeutic maintenance, effectiveness and safety of Janus kinase inhibitors in rheumatoid arthritis before and after PRAC recommendations (ACR Convergence 2026) - Sep 8, 2026 - Abstract #0466; Pres time: Nov 8, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; " We conducted a retrospective single-centre cohort study including consecutive RA patients initiating a first JAK inhibitor (tofacitinib, baricitinib, upadacitinib or filgotinib) between April 2018 and November 2023. The present study demonstrated that the therapeutic maintenance of JAKi in RA exhibited a relatively high rate of occurrence at 12 and 24 months. Primarily utilized as a third-line targeted therapy, JAKi has been demonstrated to significantly improve RA activity, yielding favorable outcomes. However, a considerable proportion of patients discontinued treatment due to lack of efficacy or adverse effects, underscoring the necessity for ongoing, personalized evaluation of these therapies in routine clinical practice."
Clinical • Real-world • Real-world evidence • Cardiovascular • Immunology • Inflammatory Arthritis • Myocardial Infarction • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Venous Thromboembolism
|
|
Jérôme Avouac1; Salomé Abdellaoui2; Omar Al Tabaa3; Stephane Hilliquin4; Roberto D'Alessandro4; Sophie Hecquet4; Marion Thomas2; Sandrine Carvès2; Alice Combier2; Yannick Allanore5
|